BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 6967702)

  • 21. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
    Reed SL; Ember JA; Herdman DS; DiScipio RG; Hugli TE; Gigli I
    J Immunol; 1995 Jul; 155(1):266-74. PubMed ID: 7602103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaphylatoxin-mediated contraction of guinea pig lung strips: a nonhistamine tissue response.
    Stimler NP; Brocklehurst WE; Bloor CM; Hugli TE
    J Immunol; 1981 Jun; 126(6):2258-61. PubMed ID: 6164725
    [No Abstract]   [Full Text] [Related]  

  • 23. Anaphylatoxins inhibit C2 production.
    Lappin D; Damerau B; Whaley K
    Clin Exp Immunol; 1983 Nov; 54(2):455-60. PubMed ID: 6317240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion.
    Meuer S; Hugli TE; Andreatta RH; Hadding U; Bitter-Suermann D
    Inflammation; 1981 Dec; 5(4):263-73. PubMed ID: 6976935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaphylatoxin-mediated regulation of human and murine immune responses.
    Morgan EL; Weigle WO; Hugli TE
    Fed Proc; 1984 Jul; 43(10):2543-7. PubMed ID: 6610569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the anaphylatoxin inactivator and chemotactic factor inactivator activities during cardiopulmonary bypass.
    Kreutzer DL; McCormick JR; Despins A; Moore M; Rousou JH; Dobbs W; Engleman RN
    J Exp Pathol; 1984; 1(3):183-7. PubMed ID: 6336305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac anaphylaxis. Complement activation as an amplification system.
    del Balzo U; Polley MJ; Levi R
    Circ Res; 1989 Sep; 65(3):847-57. PubMed ID: 2475275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anaphylatoxin levels in human vitreous humor.
    Mondino BJ; Sidikaro Y; Sumner H
    Invest Ophthalmol Vis Sci; 1988 Jul; 29(7):1195-8. PubMed ID: 3262096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity.
    Bautsch W; Kretzschmar T; Stühmer T; Kola A; Emde M; Köhl J; Klos A; Bitter-Suermann D
    Biochem J; 1992 Nov; 288 ( Pt 1)(Pt 1):261-6. PubMed ID: 1445269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the binding of fluorescent C5a and C3a to human peripheral blood leukocytes.
    van Epps DE; Chenoweth DE
    J Immunol; 1984 Jun; 132(6):2862-7. PubMed ID: 6373920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amino acid sequence of guinea pig C3a anaphylatoxin.
    Gerard NP; Lively MO; Gerard C
    Protein Seq Data Anal; 1988; 1(6):473-8. PubMed ID: 3064079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.
    Takabayashi T; Shimizu S; Clark BD; Beinborn M; Burke JF; Gelfand JA
    Surgery; 2004 May; 135(5):544-54. PubMed ID: 15118592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaphylatoxin-induced release of histamine from in vitro perfused guinea pig kidney.
    Abdullah NA; Assem ES; Damerau B
    Agents Actions; 1988 Apr; 23(3-4):181-4. PubMed ID: 2455983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaphylatoxin-induced histamine release with human leukocytes: studies of C3a leukocyte binding and histamine release.
    Glovsky MM; Hugli TE; Ishizaka T; Lichtenstein LM; Erickson BW
    J Clin Invest; 1979 Sep; 64(3):804-11. PubMed ID: 89118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.
    Fernandez HN; Hugli TE
    J Immunol; 1976 Nov; 117(5 Pt 1):1688-94. PubMed ID: 1002996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The anaphylatoxic peptide C3a of guinea pig complement. I. Purification, physicochemical and antigenetic properties.
    Meuer S; Becker S; Hadding U; Bitter-Suermann D
    Z Immunitatsforsch Immunobiol; 1978 Mar; 154(2):135-46. PubMed ID: 77089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A role for the C3a anaphylatoxin receptor in the effector phase of asthma.
    Humbles AA; Lu B; Nilsson CA; Lilly C; Israel E; Fujiwara Y; Gerard NP; Gerard C
    Nature; 2000 Aug; 406(6799):998-1001. PubMed ID: 10984054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet-serotonin release by C3a and C5a: two independent pathways of activation.
    Meuer S; Ecker U; Hadding U; Bitter-Suermann D
    J Immunol; 1981 Apr; 126(4):1506-9. PubMed ID: 7204973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of the anaphylatoxins C3a and C5a on isolated mast cells from rat and man.
    Jürgensen H; Behrendt H; Damerau B; Schmutzler W
    Agents Actions; 1986 Apr; 18(1-2):153-4. PubMed ID: 2425572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proceedings: Effect of the complement-derived peptides C3a and C5a (anaphylatoxin) on platelets of different species, in vitro.
    Grossklaus C; Damerau B; Vogt W
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R59. PubMed ID: 1143463
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.